explore -WSS

explore

author：knowledge 2025-10-01 00:48:10 - browse：72784

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Why Talkspace is targeting Medicare, a tricky market

hotspot

WSS

Ancient Greek ideas underpin modern concepts of pregnancy

Immune cells and nerve overgrowth may explain recurring UTI pain

He's 19 months old and has one of the world’s rarest diseases

Megan Rapinoe shares emotional post following US Women's World Cup exit

Judge sides with young activists in first

Immune cells and nerve overgrowth may explain recurring UTI pain

knowledge

explore

leisure time

Psychedelics group wrestles with new pharma identity

Dozens dead from Maui wildfires: What we know about the victims

Hepatitis C has a cure — but many Americans still lack access to it

Lack of health data on LGBTQ+ people has serious consequences

Apple is now the first public company to be valued at $3 trillion

YouTube cracks down on misinformation on cancer treatment

Medicare details structure of new drug price negotiation program

Maui wildfire now ranks as the fifth

Apple is now the first public company to be valued at $3 trillion

Surge in Apellis stock fueled by confidence in safety of its eye drug

focus

Harvard's David Sinclair gets blowback over aging

Illumina slashes 2023 revenue projections yet again

The untold story of TV’s first prescription drug ad